STOCK TITAN

Equity awards and tax-related share sale for uniQure (QURE) CEO

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

uniQure N.V. CEO and managing director Matthew C. Kapusta reported new equity compensation grants and a small related share sale. He was granted stock options for 113,800 shares at an exercise price of $0.00 per share and 70,600 restricted share units, each representing one ordinary share.

The restricted share units vest in three equal annual installments beginning on the first anniversary of the grant date, subject to his continued service. The stock options vest 25% on the first anniversary and 6.25% quarterly thereafter until fully vested. In a separate transaction, 14,581 ordinary shares were sold at a weighted average price of $9.06 per share, within a range of $9.00 to $9.22, solely to cover estimated withholding taxes under automatic sale instructions, and were not a discretionary trade.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kapusta Matthew C

(Last) (First) (Middle)
C/O UNIQURE N.V.
PAASHEUVELWEG 25A

(Street)
AMSTERDAM P7 11058BP

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
uniQure N.V. [ QURE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CEO, Managing Director
3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 03/04/2026 A 70,600(1) A $0 675,239 D
Ordinary Shares 03/04/2026 S(2) 14,581(2) D $9.06(3) 660,658 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $9.04 03/04/2026 A 113,800 (4) 03/04/2036 Ordinary Shares 113,800 $0 113,800 D
Explanation of Responses:
1. Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates.
2. The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.22. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
4. The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates.
/s/ Christian Klemt, Attorney-in-Fact 03/06/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did uniQure (QURE) grant its CEO Matthew Kapusta?

uniQure granted CEO Matthew Kapusta stock options for 113,800 shares and 70,600 restricted share units. Each restricted unit equals one ordinary share, providing long-term equity-based compensation tied to continued service and future vesting milestones under the company’s share incentive plan.

How do Matthew Kapusta’s new restricted share units in uniQure (QURE) vest?

Kapusta’s restricted share units vest in three equal annual installments, starting on the first anniversary of the grant date. Vesting depends on his continued relationship with uniQure, aligning his long-term incentives with the company’s performance and retention objectives over multiple years.

What is the vesting schedule for the new uniQure (QURE) stock options granted to the CEO?

The stock options granted to Kapusta vest 25% on the first anniversary of the grant date, then 6.25% each quarter until fully vested. This gradual vesting schedule encourages ongoing tenure and links compensation to long-term shareholder value creation.

Why did uniQure (QURE) CEO Matthew Kapusta sell 14,581 shares?

Kapusta sold 14,581 ordinary shares solely to cover estimated withholding taxes triggered by vesting restricted share units. The sale followed automatic instructions in the RSU agreement and was not a discretionary trade, reflecting standard tax withholding mechanics for equity awards.

At what prices were the uniQure (QURE) shares sold for tax withholding?

The 14,581 shares were sold at a weighted average price of $9.06, in multiple trades between $9.00 and $9.22. The filing notes the CEO can provide full trade details upon request to the company, shareholders, or regulators.

How many uniQure (QURE) ordinary shares does Matthew Kapusta hold after these transactions?

After reporting these transactions, Kapusta directly holds 660,658 ordinary shares of uniQure. This figure reflects the net result of newly acquired vested shares and the tax-related sale disclosed in the Form 4 insider transaction report.
Uniqure

NASDAQ:QURE

QURE Rankings

QURE Latest News

QURE Latest SEC Filings

QURE Stock Data

663.41M
58.14M
Biotechnology
Pharmaceutical Preparations
Link
Netherlands
AMSTERDAM